Aprea Therapeutics, Inc.

Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Doylestown, Pennsylvania, focused on developing and commercializing novel cancer therapeutics that target DNA damage response (DDR) pathways. The company develops small molecule inhibitors designed to exploit genetic mutations in cancer, aiming to maximize clinical activity while minimizing toxicity through increased selectivity. Its lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small molecule ATR inhibitor, both in clinical development for solid tumor indications. Aprea's technology has potential applications across multiple cancer types, including ovarian, colorectal, prostate, and breast cancers.

Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Doylestown, Pennsylvania, focused on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. The company's approach exploits vulnerabilities associated with cancer cell mutations, designed to kill tumors while minimizing effects on normal, healthy cells. Its lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small molecule ATR inhibitor, both in clinical development for solid tumor indications. Oren Gilad, Ph.D., has served as Chief Executive Officer of Aprea Therapeutics since July 2022 and as President and a member of its Board of Directors since May 2022.

Aprea Therapeutics embraces the latest advancements in precision medicine and targeted cancer therapies, focusing on matching treatments to specific cancer-related genetic mutations to potentially maximize effectiveness and minimize side effects.

• APR-1051

  An oral, small-molecule inhibitor of WEE1 kinase in clinical development for solid tumor indications.

• ATRN-119

  A small molecule ATR inhibitor in clinical development for solid tumor indications.

1. 1Aprea Therapeutics | DDR-Targeted Therapyaprea.com
2. 2Aprea Therapeutics | Leaders in DDR-Targeted Solutionsaprea.com
3. 3Aprea Therapeutics Appoints Fouad Namouni, M.D. and Richard Peters, M.D., Ph.D. to Board of Directorsbiospace.com